 | Up a level |
2018
Mollaoglu, G., Chalishazar, M., Huang, F., Guthrie, M., Bohm, S., Breagelmann, J., Sen, T., Byers, L., Johnson, J., Wechsler-Reya, R., Gazdar, A., Deberardinis, R., Sos, M. and Oliver, T. (2018). Genetic Mouse Models (GEMMS). J. Thorac. Oncol., 13 (10). S. S307 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
2017
Michels, S., Plenker, D., Wagener, S., Scheffler, M., Nogova, L., Abdulla, D., Riedel, R., Bunck, A., Merkelbach-Bruse, S., Buettner, R., Sos, M. and Wolf, J. (2017). Loss of ROS1 G2032R resistance mutation upon chemotherapy treatment enables successful crizotinib rechallenge in a ROS1-rearranged NSCLC patient. Oncol. Res. Treat., 40. S. 232 - 233. BASEL: KARGER. ISSN 2296-5262
2016
Michels, S., Fischer, R., Heydt, C., Ihle, M., Scheffler, M., Scheel, A., Ortiz-Cuaran, S., Nogova, L., Brandes, V, Sos, M., Buettner, R., Merkelbach-Bruse, S. and Wolf, J. (2016). Mechanisms of primary and acquired resistance to 3rd generation EGFR TKI treatment in EGFR mutated lung adenocarcinoma. Oncol. Res. Treat., 39. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262
2014
Nogova, L., Gardizi, M., Bos, M., Scheffler, M., Papachristou, I., Woempner, C., Heukamp, L., Schildhaus, H. -U., Fuhr, U., Sos, M., Eberhardt, W., Wiesweg, M., Schmid, K. W., Schuler, M., Thomas, R., Buettner, R. and Wolf, J. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Buettner, R., Elter, T., Toepelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T. and Wolf, J. (2014). MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262